Aeries Technology, Inc. (AERT): Nasdaq/NYSE listing notice — Aeries Technology receives Nasdaq bid-price deficiency notice; cure period until Aug 19, 2025

Aeries Technology, Inc.

Nasdaq notified AERT on Feb 20, 2025 that shares closed below $1.00 for 30 consecutive business days through Feb 19.
Company has 180 calendar days, until August 19, 2025, to regain compliance; shares continue trading on Nasdaq.
To cure, bid price must close at or above $1.00 for at least 10 consecutive business days before Compliance Date.
If not cured by Aug 19, AERT may seek an additional 180-day period or effect a reverse stock split.
Company will monitor and evaluate options but provides no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

Aeries Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 20, 2025, Aeries Technology, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from December 31, 2024 to February 19, 2025, the Company’s Class A ordinary shares had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Notice does not impact the listing of the Company’s Clas

View on SEC.gov

Browse all listing & compliance notices →

Aeries Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-25-001226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.